Doron Therapeutics is a clinical-stage biotechnology company developing MOTYS™, a Phase 3 ready intra-articular biologic drug derived from placental tissue that delivers growth factors with anti-inflammatory and regenerative properties. This treatment targets the progressive degeneration of osteoarthritis, aiming to restore joint function and improve mobility for affected patients.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Osteoarthritis leads to progressive joint degeneration, causing pain, reduced mobility, and diminished quality of life for affected individuals. Current treatments often fail to address the underlying tissue damage and provide only symptomatic relief. There is a need for therapies that can promote joint regeneration and restore function.
Solution
Doron Therapeutics is developing MOTYS™, an intra-articular biologic drug derived from placental tissue, to treat osteoarthritis. MOTYS™ delivers growth factors with anti-inflammatory and regenerative properties directly into the affected joint. This approach aims to address the progressive degeneration of osteoarthritis by promoting tissue repair and restoring joint function. The drug is currently Phase 3 ready.
Target Audience
The primary target audience includes patients suffering from osteoarthritis and healthcare providers specializing in orthopedics and rheumatology.
Features
- Intra-articular delivery for targeted treatment of affected joints
- Biologic drug derived from placental tissue, rich in growth factors
- Anti-inflammatory properties to reduce pain and swelling
- Regenerative capabilities to promote tissue repair
- Phase 3 ready, indicating advanced stage of clinical development